Hims & Hers Health is betting that the cash-pay market for weight-loss drugs will drive up customer demand although some ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, diminishing the likelihood of a partnership with one most visible players in the ...

NB.1.8.1 has mutations that could increase the virus’s transmissibility and decrease the efficacy of certain neutralizing ...

Health-care companies rose amid sales growth optimism. Drug-store chain CVS Health said it has seen complaints of strong push back from patients on its pharmacy-benefit manager's move to favor Novo ...

Hims & Hers Health Inc (NYSE:HIMS) stock fell 3.8% Tuesday after Eli Lilly and Company (NYSE:LLY) indicated it would not partner with telehealth firms selling copycat versions of weight-loss drugs, ...

Researchers found that injectable GLP-1 receptor agonists for obesity tended to yield smaller reductions in weight in ...

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

Back-to-back studies map complementary hunger and satiety pathways, offering clues to refine weight-loss drugs.

CHICAGO -- Physicians debated the idea of the American Medical Association (AMA) supporting a registry to track adverse ...

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as ...